A diagnostic test to examine early improvement as a predictor of later response to lurasidone in bipolar depression
Abstract Introduction Kato et al. reported results of a 6‐week, double‐blind, randomized, placebo‐controlled trial of lurasidone in adults with bipolar depression (BDep). Aim We performed a post hoc analysis using data from the lurasidone trial to predict later responses from early improvements. Met...
Saved in:
Main Authors: | Taro Kishi (Author), Hiroshi Nakamura (Author), Tadafumi Kato (Author), Nakao Iwata (Author) |
---|---|
Format: | Book |
Published: |
Wiley,
2023-03-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Lurasidone, olanzapine, and quetiapine extended‐release for bipolar depression: A systematic review and network meta‐analysis of phase 3 trials in Japan
by: Taro Kishi, et al.
Published: (2020) -
Management of bipolar I depression: clinical utility of lurasidone
by: Findlay LJ, et al.
Published: (2015) -
Post‐marketing surveillance of quetiapine fumarate extended‐release tablets in patients with bipolar depression
by: Taro Kishi, et al.
Published: (2024) -
Quetiapine extended‐release vs olanzapine for Japanese patients with bipolar depression: A Bayesian analysis
by: Taro Kishi, et al.
Published: (2019) -
Efficacy, tolerability, and safety of lurasidone for acute schizophrenia: A systematic review and network meta‐analysis of phase 3 trials in Japan
by: Taro Kishi, et al.
Published: (2020)